RCAG
REGN icon

Rehmann Capital Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Rehmann Capital Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.85M Buy
2,393
+22
+0.9% +$16.8K 0.1% 150
2025
Q4 		$1.83M Buy
2,371
+223
+10% +$151K 0.1% 150
2025
Q3 		$1.21M Buy
2,148
+465
+28% +$263K 0.07% 200
2025
Q2 		$884K Buy
1,683
+231
+16% +$129K 0.05% 237
2025
Q1 		$921K Buy
1,452
+770
+113% +$530K 0.06% 235
2024
Q4 		$487K Buy
682
+144
+27% +$121K 0.03% 354
2024
Q3 		$572K Sell
538
-93
-15% -$103K 0.04% 317
2024
Q2 		$663K Buy
631
+30
+5% +$29.1K 0.05% 267
2024
Q1 		$578K Buy
601
+76
+14% +$72.3K 0.04% 290
2023
Q4 		$461K Buy
525
+42
+9% +$34.6K 0.04% 329
2023
Q3 		$397K Buy
483
+20
+4% +$15.7K 0.04% 339
2023
Q2 		$333K Buy
463
+13
+3% +$10K 0.03% 398
2023
Q1 		$370K Buy
450
+50
+13% +$37.7K 0.03% 369
2022
Q4 		$289K Sell
400
-63
-14% -$46.5K 0.03% 426
2022
Q3 		$319K Buy
463
+8
+2% +$5.04K 0.04% 362
2022
Q2 		$269K Sell
455
-541
-54% -$352K 0.03% 398
2022
Q1 		$696K Buy
996
+49
+5% +$31K 0.07% 257
2021
Q4 		$601K Buy
947
+44
+5% +$27.1K 0.06% 280
2021
Q3 		$546K Buy
903
+31
+4% +$19.2K 0.05% 303
2021
Q2 		$490K Sell
872
-124
-12% -$62.8K 0.05% 313
2021
Q1 		$472K Buy
996
+81
+9% +$39.4K 0.05% 298
2020
Q4 		$442K Buy
+915
New +$494K 0.05% 289
2019
Q3 		$1.94K Sell
7
-5
-42% -$1.48K ﹤0.01% 1417
2019
Q2 		$3.76K Sell
12
-198
-94% -$65.9K ﹤0.01% 1624
2019
Q1 		$86.2K Buy
210
+50
+31% +$20.6K 0.01% 634
2018
Q4 		$59.8K Buy
160
+88
+122% +$32.2K 0.01% 538
2018
Q3 		$29.1K Buy
72
+68
+1,700% +$25.9K ﹤0.01% 999
2018
Q2 		$1.38K Sell
4
-44
-92% -$13.8K ﹤0.01% 1896
2018
Q1 		$17K Buy
+48
New +$16.7K ﹤0.01% 1134

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Rehmann Capital Advisory Group's REGN Position: Q1 2026 in Review

Rehmann Capital Advisory Group increased its Regeneron Pharmaceuticals (REGN) stake by 0.93% in Q1 2026, buying an estimated $16.8K and bringing the position to 2,393 shares worth $1.85M. The position accounts for 0.1% of the portfolio, ranked #150.

Rehmann Capital Advisory Group first reported a position in REGN in Q1 2018 and has held it in 29 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Rehmann Capital Advisory Group held 2,393 shares of Regeneron Pharmaceuticals worth $1.85M as of Q1 2026.
  • Rehmann Capital Advisory Group bought 22 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $16.8K.
  • Regeneron Pharmaceuticals made up 0.1% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #150 holding.
  • Rehmann Capital Advisory Group first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 29 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.